NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVTA shares have increased by 87.8% and is now trading at $29.76.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) released its quarterly earnings data on Tuesday, August, 4th. The medical research company reported ($0.77) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.15. The medical research company had revenue of $46.20 million for the quarter, compared to analyst estimates of $39.63 million. InVitae had a negative return on equity of 77.82% and a negative net margin of 182.73%. The business's revenue was down 14.4% compared to the same quarter last year. During the same period last year, the business earned ($0.54) earnings per share.
View InVitae's earnings history.

6 analysts have issued 12-month target prices for InVitae's stock. Their forecasts range from $20.00 to $37.25. On average, they expect InVitae's stock price to reach $32.54 in the next year. This suggests a possible upside of 9.3% from the stock's current price.
View analysts' price targets for InVitae.

News headlines about NVTA stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. InVitae earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about InVitae.

Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC) and Enzo Biochem (ENZ).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Shopify (SHOP), Trade Desk (TTD), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Okta (OKTA) and Twilio (TWLO).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Macquarie Group Ltd. (3.01%), Bank of New York Mellon Corp (1.15%), Victory Capital Management Inc. (0.83%), Goldman Sachs Group Inc. (0.73%) and Jennison Associates LLC (0.31%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Principal Financial Group Inc., Goldman Sachs Group Inc., PNC Financial Services Group Inc., Profit Investment Management LLC, Bank of Montreal Can, and CAPROCK Group Inc.. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Victory Capital Management Inc., FMR LLC, Fagan Associates Inc., Bank of New York Mellon Corp, Barclays PLC, Mackay Shields LLC, and Mutual of America Capital Management LLC.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $29.76.

InVitae has a market capitalization of $3.92 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]